SC
PACB icon

Shay Capital’s Pacific Biosciences PACB Stock Holding History

Shay Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-75,000
Closed -$626K – 378
2023
Q3 		$626K Buy
+75,000
New +$857K 0.09% 146
2021
Q3 		– Sell
-20,000
Closed -$699K – 662
2021
Q2 		$699K Buy
+20,000
New +$582K 0.08% 214

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Shay Capital's PACB Position: Q4 2023 in Review

Shay Capital sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 75,000 shares — an estimated $626K sold.

Shay Capital first reported a position in PACB in Q2 2021 and held it in 2 quarters. The position peaked at $699K in Q2 2021. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

  • Shay Capital reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
  • Shay Capital sold 75,000 Pacific Biosciences shares in Q4 2023, an estimated $626K.
  • Shay Capital first reported a position in Pacific Biosciences in Q2 2021 and held it in 2 quarters.
  • Shay Capital's Pacific Biosciences position peaked at $699K in Q2 2021.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Shay Capital's 13F filing for Q4 2023, filed 14 Feb 2024.